```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:X

LOGINID:SSSPTA1644PNH

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAR 15   WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS  3  MAR 16   CASREACT coverage extended
 NEWS  4  MAR 20   MARPAT now updated daily
 NEWS  5  MAR 22   LWPI reloaded
 NEWS  6  MAR 30   RDISCLOSURE reloaded with enhancements
 NEWS  7  APR 02   JICST-EPLUS removed from database clusters and STN
 NEWS  8  APR 30   GENBANK reloaded and enhanced with Genome Project ID field
 NEWS  9  APR 30   CHEMCATS enhanced with 1.2 million new records
 NEWS 10  APR 30   CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 11  APR 30   INPADOC replaced by INPADOCDB on STN
 NEWS 12  MAY 01   New CAS web site launched
 NEWS 13  MAY 08   CA/CAplus Indian patent publication number format defined
 NEWS 14  MAY 14   RDISCLOSURE on STN Easy enhanced with new search and display
                   fields
 NEWS 15  MAY 21   BIOSIS reloaded and enhanced with archival data
 NEWS 16  MAY 21   TOXCENTER enhanced with BIOSIS reload
 NEWS 17  MAY 21   CA/CAplus enhanced with additional kind codes for German
                   patents
 NEWS 18  MAY 22   CA/CAplus enhanced with IPC reclassification in Japanese
                   patents
 NEWS 19  JUN 27   CA/CAplus enhanced with pre-1967 CAS Registry Numbers
 NEWS 20  JUN 29   STN Viewer now available
 NEWS 21  JUN 29   STN Express, Version 8.2, now available
 NEWS 22  JUL 02   LEMBASE coverage updated
 NEWS 23  JUL 02   LMEDLINE coverage updated
 NEWS 24  JUL 02   SCISEARCH enhanced with complete author names
 NEWS 25  JUL 02   CHEMCATS accession numbers revised
 NEWS 26  JUL 02   CA/CAplus enhanced with utility model patents from China
 NEWS 27  JUL 16   CAplus enhanced with French and German abstracts
 NEWS 28  JUL 18   CA/CAplus patent coverage enhanced
 NEWS 29  JUL 26   USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS 30  JUL 30   USGENE now available on STN

 NEWS EXPRESS  29 JUNE 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
```

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:53:31 ON 02 AUG 2007

=> file medline embase biosis scisearch caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 13:53:47 ON 02 AUG 2007

FILE 'EMBASE' ENTERED AT 13:53:47 ON 02 AUG 2007

FILE 'BIOSIS' ENTERED AT 13:53:47 ON 02 AUG 2007

FILE 'SCISEARCH' ENTERED AT 13:53:47 ON 02 AUG 2007

FILE 'CAPLUS' ENTERED AT 13:53:47 ON 02 AUG 2007

=> s CTL epitope
L1 6610 CTL EPITOPE

=> s l1 and KDR
L2 1 L1 AND KDR

=> d l2 cbib abs

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
2000:240985 Document No. 132:292701 Novel methods for therapeutic vaccination. Steinaa, Lucilla; Mouritsen, Soren; Nielsen, Klaus Gregorious; Haaning, Jesper; Leach, Dana; Dalum, Iben; Gautam, Anand; Birk, Peter; Karlsson, Gunilla (M & E Biotech A/S, Den.). PCT Int. Appl. WO 2000020027 A2 20000413, 220 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-DK525 19991005. PRIORITY: DK 1998-1261 19981005; US 1998-PV105011 19981020.

AB A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one **CTL epitope** of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. prostate specific membrane antigen (PSM), Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogs of PSM, Her2 and FGF8b, as well as nucleic acid mols. encoding these analogs. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogs of weak or non-immunogenic antigens.

```
=> s KDR
L3         9651 KDR

=> s l3 and nonopeptide
L4            0 L3 AND NONOPEPTIDE

=> s l3 and peptide
L5          637 L3 AND PEPTIDE

=> s l5 and CTL
L6            6 L5 AND CTL

=> dup reove l6
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
'REOVE' IS NOT VALID.  VALID FILE NAMES ARE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH,
CAPLUS'
You have entered a file name of duplicates to keep that is not
referenced by any of the L#s specified for this DUPLICATE command.
The file names of duplicates that can be kept are listed above.
Please enter one of these file names.

=> dup remove l6
PROCESSING COMPLETED FOR L6
L7             2 DUP REMOVE L6 (4 DUPLICATES REMOVED)

=> d l7 1-2 cbib abs

L7   ANSWER 1 OF 2     MEDLINE on STN                    DUPLICATE 1
2006075035.    PubMed ID: 16234362.   The kinase insert domain-containing
     receptor is an angiogenesis-associated antigen recognized by human
     cytotoxic T lymphocytes. Sun Yuansheng; Stevanovic Stefan; Song Mingxia;
     Schwantes Astrid; Kirkpatrick C James; Schadendorf Dirk; Cichutek Klaus.
     (Division of Medical Biotechnology, Paul-Ehrlich-Institute,
     Paul-Ehrlich-Str 51-59, D-63225 Langen, Germany.. sunyu@pei.de) . Blood,
     (2006 Feb 15) Vol. 107, No. 4, pp. 1476-83.  Electronic Publication:
     2005-10-18. Journal code: 7603509. ISSN: 0006-4971. Pub. country: United
     States. Language: English.
AB   Antigen-specific cancer immunotherapy directed toward tumor-nourishing
     angiogenic blood vessels holds the promise of high efficacy, low toxicity,
     and ease of application.  To evaluate whether the human angiogenic kinase
     insert domain-containing receptor (KDR) can serve as a target
     for cellular immunotherapy, 19 peptide sequences with HLA-A*0201
     motifs were selected by computer-based algorithms.  Five peptides
     (KDR82-90, KDR288-297, KDR766-774, KDR1093-1101, KDR1035-1044) stimulated
     specific cytotoxic T lymphocytes (CTLs) from peripheral-blood
     mononuclear cells (PBMCs) of 3 HLA-A*0201 donors.  The decapeptide
     KDR288-297 was efficient in sensitizing target cells for recognition by a
     CTL clone at a concentration of 10 nM.  More important,
     KDR288-297-specific CTLs lysed target cells transfected with
     HLA-A2/KDR cDNAs and a range of HLA-matched KDR+
     angiogenic endothelial cells (aECs) and also recognized CD34+ endothelial
     progenitor cells.  The specificity of CTLs was further confirmed
     by tetramer assay and cold-target inhibition assay.  In addition, ex vivo
     exposure of aECs to the inflammatory cytokines enhanced CTL
     reactivity, which is in keeping with up-regulated KDR and HLA
     class 1 expression.  In Matrigel assays, recognition of aECs by specific
     CTLs triggered an antivascular effect.  These findings provide the
     first proof of the antigenic property of KDR protein and may be
     useful for devising new immunotherapeutic approaches to human cancers.

L7   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
2000:240985   Document No. 132:292701  Novel methods for therapeutic
     vaccination.  Steinaa, Lucilla; Mouritsen, Soren; Nielsen, Klaus
```

Gregorious; Haaning, Jesper; Leach, Dana; Dalum, Iben; Gautam, Anand; Birk, Peter; Karlsson, Gunilla (M & E Biotech A/S, Den.). PCT Int. Appl. WO 2000020027 A2 20000413, 220 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-DK525 19991005. PRIORITY: DK 1998-1261 19981005; US 1998-PV105011 19981020.

AB A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one **CTL** epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. prostate specific membrane antigen (PSM), Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogs of PSM, Her2 and FGF8b, as well as nucleic acid mols. encoding these analogs. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogs of weak or non-immunogenic antigens.

```
=> s (tahara h?/au or wada s?/au or tsunoda t?/au)
L8        12870 (TAHARA H?/AU OR WADA S?/AU OR TSUNODA T?/AU)

=> s l8 and KDR petpides
L9            0 L8 AND KDR PETPIDES

=> s l8 and KDR peptides
L10           0 L8 AND KDR PEPTIDES

=> s l8 adn KDR
MISSING OPERATOR L8 ADN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l8 and KDR
L11           2 L8 AND KDR

=> dup remove l11
PROCESSING COMPLETED FOR L11
L12           2 DUP REMOVE L11 (0 DUPLICATES REMOVED)

=> d l12 1-2 cbib abs

L12  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
2004:252541   Document No. 140:269532  KDR receptor-derived
     HLA-A*2402- and HLA-A*0201-binding epitopes for angiogenesis inhibition
     and as vaccines against cancer, diabetic retinopathy, chronic rheumatoid
     arthritis, psoriasis and atherosclerosis.  Tahara, Hideaki;
     Wada, Satoshi; Tsunoda, Takuya (Oncotherapy Science,
     Inc., Japan).  PCT Int. Appl. WO 2004024766 A1 20040325, 100 pp.
     DESIGNATED STATES: W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ,
     CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
     GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
     LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH,
     PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
     UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI,
```

CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2003-JP11722 20030912. PRIORITY: JP 2002-267285 20020912; JP 2003-62003 20030307; JP 2003-167042 20030611.

AB It is intended to provide a nonapeptide selected from among peptides comprising the amino acid sequences represented by SEQ ID NOS:2, 3, 5, 8, 11 and 12; a nonapeptide or a decapeptide selected from among peptides comprising the amino acid sequences represented by SEQ ID NOS:29, 30, 33, 34, 40 and 46; a peptide having an amino acid sequence derived from any of the above amino acid sequences by substitution or addition of one to several amino acids and being capable of inducing cytotoxic T cells; and drugs containing such a peptide for treating or preventing tumor. These **KDR** receptor-derived nona- and deca-peptides are HLA-A*2402-binding or HLA-A*0201-binding epitopes. These HLA-A*2402-binding and HLA-A*0201-binding epitope epitopes are useful for angiogenesis inhibition and as vaccines against cancer, diabetic retinopathy, chronic rheumatoid arthritis, psoriasis and atherosclerosis.

L12 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
2003:441992 Document No.: PREV200300441992. Development of cancer immunotherapy against tumor angiogenesis. **Wada, Satoshi** [Reprint Author]; **Tsunoda, Takuya** [Reprint Author]; Baba, Toshiyuki [Reprint Author]; **Tahara, Hideaki** [Reprint Author]. Institute of Medical Science, University of Tokyo, Tokyo, Japan. Proceedings of the American Association for Cancer Research Annual Meeting, (July 2003) Vol. 44, pp. 167. print.
Meeting Info.: 94th Annual Meeting of the American Association for Cancer Research. Washington, DC, USA. July 11-14, 2003.
ISSN: 0197-016X. Language: English.

```
=> d his

     (FILE 'HOME' ENTERED AT 13:53:31 ON 02 AUG 2007)

     FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 13:53:47 ON
     02 AUG 2007
L1          6610 S CTL EPITOPE
L2             1 S L1 AND KDR
L3          9651 S KDR
L4             0 S L3 AND NONOPEPTIDE
L5           637 S L3 AND PEPTIDE
L6             6 S L5 AND CTL
L7             2 DUP REMOVE L6 (4 DUPLICATES REMOVED)
L8         12870 S (TAHARA H?/AU OR WADA S?/AU OR TSUNODA T?/AU)
L9             0 S L8 AND KDR PETPIDES
L10            0 S L8 AND KDR PEPTIDES
L11            2 S L8 AND KDR
L12            2 DUP REMOVE L11 (0 DUPLICATES REMOVED)

=> s l3 and peptide?
L13          637 L3 AND PEPTIDE?

=> s l13 and pd<20020912
   2 FILES SEARCHED...
   4 FILES SEARCHED...
L14          289 L13 AND PD<20020912

=> s k14 and T cell epitope
L15            0 K14 AND T CELL EPITOPE

=> s l13 and cytotoxic T cell
L16            2 L13 AND CYTOTOXIC T CELL

=> d 16 1-2 cbib abs
```

L6 ANSWER 1 OF 6 MEDLINE on STN

2006075035. PubMed ID: 16234362. The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Sun Yuansheng; Stevanovic Stefan; Song Mingxia; Schwantes Astrid; Kirkpatrick C James; Schadendorf Dirk; Cichutek Klaus. (Division of Medical Biotechnology, Paul-Ehrlich-Institute, Paul-Ehrlich-Str 51-59, D-63225 Langen, Germany.. sunyu@pei.de) . Blood, (2006 Feb 15) Vol. 107, No. 4, pp. 1476-83. Electronic Publication: 2005-10-18. Journal code: 7603509. ISSN: 0006-4971. Pub. country: United States. Language: English.

AB Antigen-specific cancer immunotherapy directed toward tumor-nourishing angiogenic blood vessels holds the promise of high efficacy, low toxicity, and ease of application. To evaluate whether the human angiogenic kinase insert domain-containing receptor (**KDR**) can serve as a target for cellular immunotherapy, 19 **peptide** sequences with HLA-A*0201 motifs were selected by computer-based algorithms. Five **peptides** (KDR82-90, KDR288-297, KDR766-774, KDR1093-1101, KDR1035-1044) stimulated specific cytotoxic T lymphocytes (**CTLs**) from peripheral-blood mononuclear cells (PBMCs) of 3 HLA-A*0201 donors. The decapeptide KDR288-297 was efficient in sensitizing target cells for recognition by a **CTL** clone at a concentration of 10 nM. More important, KDR288-297-specific **CTLs** lysed target cells transfected with HLA-A2/**KDR** cDNAs and a range of HLA-matched **KDR**+ angiogenic endothelial cells (aECs) and also recognized CD34+ endothelial progenitor cells. The specificity of **CTLs** was further confirmed by tetramer assay and cold-target inhibition assay. In addition, ex vivo exposure of aECs to the inflammatory cytokines enhanced **CTL** reactivity, which is in keeping with up-regulated **KDR** and HLA class 1 expression. In Matrigel assays, recognition of aECs by specific **CTLs** triggered an antivascular effect. These findings provide the first proof of the antigenic property of **KDR** protein and may be useful for devising new immunotherapeutic approaches to human cancers.

L6 ANSWER 2 OF 6 EMBASE

2006082463 EMBASE The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Sun Y.; Stevanovic S.; Song M.; Schwantes A.; Kirkpatrick C.J.; Schadendorf D.; Cichutek K.. Y. Sun, Division of Medical Biotechnology, Paul-Ehrlich-Institute, Paul-Ehrlich-Str 51-59, D-63225 Langen, Germany. sunyu@pei.de. Blood Vol. 107, No. 4, pp. 1476-1483 15 Feb 2006.

Refs: 43.

ISSN: 0006-4971. E-ISSN: 0006-4971. CODEN: BLOOAW

Pub. Country: United States. Language: English. Summary Language: English.

Entered STN: 20060316. Last Updated on STN: 20060316

AB Antigen-specific cancer immunotherapy directed toward tumor-nourishing angiogenic blood vessels holds the promise of high efficacy, low toxicity, and ease of application. To evaluate whether the human angiogenic kinase insert domain-containing receptor (**KDR**) can serve as a target for cellular immunotherapy, 19 **peptide** sequences with HLA-A*0201 motifs were selected by computer-based algorithms. Five **peptides** (**KDR**(82-90), **KDR** (288-297), **KDR**(766-774), **KDR**(1093-1101), **KDR** (1035-1044)) stimulated specific cytotoxic T lymphocytes (**CTLs**) from peripheral-blood mononuclear cells (PBMCs) of 3 HLA-A*0201 donors. The decapeptide **KDR** (288-297) was efficient in sensitizing target cells for recognition by a **CTL** clone at a concentration of 10 nM. More important, **KDR** (288-297)-specific **CTLs** lysed target cells transfected with HLA-A2/**KDR** cDNAs and a range of HLA-matched **KDR**(+) angiogenic endothelial cells (aECs) and also recognized CD34(+) endothelial progenitor cells. The specificity of **CTLs** was further confirmed by tetramer assay and cold-target inhibition assay. In addition, ex vivo exposure of aECs to the inflammatory cytokines

enhanced **CTL** reactivity, which is in keeping with up-regulated **KDR** and HLA class 1 expression. In Matrigel assays, recognition of aECs by specific **CTLs** triggered an antivascular effect. These findings provide the first proof of the antigenic property of **KDR** protein and may be useful for devising new immunotherapeutic approaches to human cancers. .COPYRGT. 2006 by The American Society of Hematology.

=> s l14 and CTL
L17 1 L14 AND CTL

=> d l17 cbib abs

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
2000:240985 Document No. 132:292701 Novel methods for therapeutic vaccination. Steinaa, Lucilla; Mouritsen, Soren; Nielsen, Klaus Gregorious; Haaning, Jesper; Leach, Dana; Dalum, Iben; Gautam, Anand; Birk, Peter; Karlsson, Gunilla (M & E Biotech A/S, Den.). PCT Int. Appl. WO 2000020027 A2 **20000413**, 220 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-DK525 19991005. PRIORITY: DK 1998-1261 19981005; US 1998-PV105011 19981020.
AB A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one **CTL** epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. prostate specific membrane antigen (PSM), Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogs of PSM, Her2 and FGF8b, as well as nucleic acid mols. encoding these analogs. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogs of weak or non-immunogenic antigens.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	78.90	79.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.12

STN INTERNATIONAL LOGOFF AT 13:59:43 ON 02 AUG 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSSPTA1644PNH

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 24	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific